Tokyo, November 18, 2016 – Kaken Pharmaceutical Co., Ltd. (“Kaken”) announced that REGROTH® Dental Kit (600µg & 1200µg), a medicinal product for periodontal regeneration [generic name: Trafermin (genetical recombination); hereinafter “REGROTH®”] was listed on the National Health Insurance (NHI) drug reimbursement price list. Kaken plans to launch REGROTH® on December 1, 2016 in Japan.
REGROTH® is the world’s first pharmaceutical developed for the purpose of periodontal regeneration. The recombinant human bFGF (basic fibroblast growth factor) is the main active ingredient. REGROTH® is the topical solution kit that is dissolved at the time of use and has an adequate viscosity. REGROTH® demonstrated both effectively and safely regenerating periodontal tissue when it is applied to the destroyed alveolar bone during gingival flap surgery. This effectiveness includes an increase in the alveolar bone height.
When Kaken will launch REGROTH® in the market, for certain implementation of the safety measures and appropriate distribution of REGROTH® in dental field, Kaken will first work to promote proper use of REGROTH® for medical institutions that specialize in periodontal treatments, including university hospitals.
Kaken aims to help improve the quality of life for more patients by providing a new treatment option, medicinal product for periodontal regeneration.